| Drug Name |
Ziprasidone hydrochloride |
| Drug ID |
BADD_D02389 |
| Description |
Disorders such as schizophrenia and bipolar disorder can significantly impair mood, cognition, and behavior.[A190525] These mental illnesses can often be accompanied by comorbidities such as depression and substance abuse, and can significantly impact the quality of life of patients and caregivers.[A190525] Luckily, several treatment options for psychotic disorders have been introduced to market since the realization of chlorpromazine's antipsychotic properties in 1952.[A190525]
Second generation antipsychotics (commonly referred to as atypical antipsychotics) include [clozapine], [quetiapine], [olanzapine], [aripiprazole] and [ziprasidone] among others, and are generally thought to be as efficacious as first generation antipsychotics but differ in their adverse effect profiles.[A190525,A190534] First generation antipsychotics are associated with extrapyramidal adverse effects while atypical antipsychotics are linked to weight gain, impaired glucose tolerance and metabolic syndrome.[A190534,A190537]
Ziprasidone is used to treat schizophrenia and bipolar disorder.[A180748] It can effectively reduce the rate and time of relapses in schizophrenia, and can be used to treat manic episodes in bipolar disorder although the mechanism of action is unknown.[A180748] Although ziprasidone is classified as an atypical antipsychotic, it appears to have a lower incidence of metabolic adverse effects compared to other medications in the same class.[A190525] |
| Indications and Usage |
For the treatment of schizophrenia and related psychotic disorders. |
| Marketing Status |
Prescription; Discontinued |
| ATC Code |
N05AE04 |
| DrugBank ID |
DB00246
|
| KEGG ID |
D01939
|
| MeSH ID |
C092292
|
| PubChem ID |
219099
|
| TTD Drug ID |
D0R1JV
|
| NDC Product Code |
0049-0054; 42816-2001; 0904-6272; 70518-2366; 70518-0757; 50090-5420; 70518-2477; 70518-2940; 65372-1160; 59762-2001; 70518-2757; 71335-0585; 70518-1586; 50090-4821; 63187-168; 0904-6269; 63629-8150; 68724-5235; 71335-0729; 65862-702; 0781-2164; 70518-1604; 70518-1835; 65862-704; 71335-0501; 0049-0052; 65862-703; 50090-5785; 68788-7363; 55111-258; 16714-838; 70518-2367; 33342-145; 16714-837; 70518-2294; 70518-2622; 0049-0056; 0049-0058; 68180-332; 33342-147; 70518-3048; 16714-836; 0781-2168; 68001-453; 70518-2374; 63739-988; 42816-0054; 50090-3823; 55111-259; 42816-2003; 66005-0027; 42816-0056; 0904-6270; 65862-705; 63739-005; 70518-0787; 0781-2166; 59762-2004; 70518-2925; 55111-257; 70518-0782; 71335-1508; 55111-256; 65977-0084; 33342-146; 63739-508; 68001-452; 68180-334; 52562-010; 68180-333; 33342-144; 63629-3331; 68180-331; 42816-0058; 55111-801; 70518-0743; 68001-451; 68001-450; 65862-398; 0781-2167; 71335-0263; 42816-0052; 16714-835; 0904-6271; 42816-2004; 59762-2002; 63739-666; 42816-2002; 59762-2003 |
| Synonyms |
ziprasidone | ziprazidone | 5-(2-(4-(3-benzisothiazolyl)piperazinyl)ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one | ziprasidone hydrochloride | CP 88059-01 | CP-88,059-1 | CP-88,059-01 | ziprasidone hydrochloride, monohydrate | Geodon | CP 88059 | CP-88,059 |
